NewAge BIOTECH, Inc. was formed in XXXX to develop, market, and license its patented zinc peptide technology. The company has seen total revenue grow from $2.7 million in XXXX to an estimated $11.1 million in 200B. Although NewAge BIOTECH experienced a net loss of $4.5 million in XXXX, profit of $500,000 is projected in 200B. In 200A, the company’s revenue grew by 40 percent to $6.6 million from $4.7 million the prior year, while operating expenses increased by only 6.7 percent to $7.45 million from $6.98 million. Overall, the company is approaching profitability, and the zinc peptide technology is proving to be a significant platform from which to launch additional product lines.